A gist of the contents at the URL:
Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors.
Version 1.20.04
This report provides guidelines for managing the pharmacologic interactions that can result when patients are treated with protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTIs) for human immunodeficiency virus (HIV) infection together with rifamycins for tuberculosis (TB),with recommendations for their use from a group of CDC scientists and outside expert consultants; these include initial recommendations for the protease inhibitors lopinavir/ritonavir, atazanavir, and fos-amprenavir (a phosphate ester prodrug of amprenavir).
